ILiAD is a clinical-stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis.
ILiAD Biotechnologies has raised $115.0M in total funding. The most recent round was Series D. The last funding was announced in February 2026.
ILiAD Biotechnologies's investors include RA Capital Management, Janus Henderson Investors, BNP Paribas Asset Management, National Institute of Allergy and Infectious Diseases, Knott Partners.
ILiAD Biotechnologies is headquartered in New York, United States.
ILiAD is a clinical-stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis.
ILiAD Biotechnologies is at the Series D stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ILiAD Biotechnologies — Funding & Investors." VCBacked, February 10, 2026, https://www.vcbacked.co/company/iliad-biotechnologies. Accessed November 13, 2026.
VCBacked. (2026). ILiAD Biotechnologies — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/iliad-biotechnologies
{{cite web |title=ILiAD Biotechnologies — Funding & Investors |url=https://www.vcbacked.co/company/iliad-biotechnologies |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at ILiAD Biotechnologies? Request a listing update